Is dyslipidemia a risk factor for trastuzumab-induced cardiotoxicity in breast cancer patients? A systematic review and meta-analysis

• Published in: Revista portuguesa de cardiologia Vol. 42; no. 12; pp. 961 - 984
• Main Authors: Pinho, Jaime, Carvalho, Miguel, Paiva, Mariana, Teixeira-Tavares, Nuno, Costa-Santos, Cristina, Sousa, Carla
• Format: Journal Article
• Language: English
• Published: Portugal Elsevier 01.12.2023
• Subjects: Breast Neoplasms - drug therapy; Cancro da mama; Cardiotoxicidade; Cardiotoxicity - etiology; Dislipidemia; Dyslipidemias - chemically induced; Dyslipidemias - complications; Female; Humans; Quimioterapia; Risk Factors; Trastuzumab; Trastuzumab - adverse effects; Chemotherapy; Cancro da mama; Quimioterapia; Dyslipidemia; Cardiotoxicidade; Breast cancer; Cardiotoxicity; Dislipidemia; Trastuzumab
• ISSN: 0870-2551; 2174-2030
• DOI: 10.1016/j.repc.2022.10.016

Breast cancer patients undergoing trastuzumab therapy have greater risk of cardiovascular disease. Risk factors for this effect have been proposed. However, the role of dyslipidemia is not completely understood. This systematic review aimed to explore the role of dyslipidemia in trastuzumab-induced cardiotoxicity. The investigators searched MEDLINE, Scopus, and Web of Science up to October 25, 2020. A random-effects model was used to determine pooled estimates of the results. The primary endpoint was trastuzumab-induced cardiotoxicity in patients with and without dyslipidemia. A total of 39 studies were selected for inclusion in our systematic review assessing 21079 patients. One study demonstrated a statistically significant association between dyslipidemia and cardiotoxicity (OR=2.28, 95% CI 1.22-4.26, p=0.01). In all other studies, no such association was observed. Twenty-one studies including 6135 patients were eligible for meta-analysis. In this meta-analysis of unadjusted data, dyslipidemia was significantly associated with cardiotoxicity (OR=1.25, 95% CI 1.01-1.53, p=0.04, I =0%), however, a subgroup analysis of studies reporting adjusted measures did not demonstrate a significant association (OR=0.89, 95% CI 0.73-1.10, p=0.28, I =0%). This systematic review and meta-analysis did not demonstrate a significant association between dyslipidemia alone and the development of cardiotoxicity. In the absence of other relevant cardiovascular risk factors, review of lipid profile may not be obligatory, and management of patients could be performed without referral for cardio-oncology assessment. Further investigation of risk factors for trastuzumab-induced cardiotoxicity is required to confirm these results.